Vive la resistant starch: A potential treatment for metabolic dysfunction-associated steatohepatitis.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 37673032.
- Also identified by DOI 10.1016/j.cmet.2023.07.004.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Metabolic dysfunction-associated steatotic liver disease is a prevalent chronic liver disease that affects nearly a third of the global adult population. Here, we preview a randomized controlled clinical trial on the potential benefits and underlying mechanisms of using resistant starch, a prebiotic, for treating this common liver condition.
Medical subject headings
- Fatty Liver
- Resistant Starch